Home | CANbridge

News Release

CANbridge Pharmaceuticals Successfully Obtains Drug Manufacturing License Type B Certificate

2024/10/28

CANbridge Pharmaceuticals’ CAN103 for Gaucher Disease Granted Priority Review Status by CDE of the NMPA

2024/09/30

CANbridge Reports Positive Topline Data from CAN103 Pivotal Trial for Gaucher Disease in China, Plans NDA Filing in Q4 2024

2024/08/19

CANbridge’s Livmarli Is Recommended in The “ Expert Consensus on Diagnosis and Treatment of ALGS Associated Liver Disease” Published By The Chinese Journal of Pediatrics

2024/08/07

CANbridge Announces Last Patient Last Visit in CAN103 Phase 2/Registration Trial for Gaucher Disease

2024/07/08

CANbridge Announces Expansion of LIVMARLI^® Label to Include Patients as Young as 3 Months in China

2024/05/21

CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2023

2024/03/28

CANbridge and PUMCH announced the establishment of PUMCH- CANbridge Genetic Defect Rare Disease Innovation and Translation Base

2024/03/01

Livmarli mentioned as a case study The Policy Address highlights Hong Kong's strengths in research and development, emphasizing its capcity to independently approve new drugs Rare disease drugs will receive significant benefits

2023/11/15

Foundation consolidated over time and for a rosy future | 2023 China Conference on Rare Diseases closed successfully

2023/11/06

More News

Investors

Partners

Detail

Our Pipeline

We are building a pipeline of compelling investigational therapies targeting indications for which we believe gene therapy can have the greatest impact in patients with rare genetic diseases.

Rare Disease

Gene Therapy

Our Products

Hunterase®, (iduronidase-2-sulfatase) is a recombinant human Enzyme Replacement Therapy (ERT).

Livmarli is an oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter (IBAT).

NERLYNX® (Neratinlib) is a potent irreversible tyrosine kinase inhibitor, that inhibits tumor growth and metastasis through blocking pan-HER family proteins (HER1, HER2, and HER4) and downstream signal transduction.

Click for more

Investor Relations